Thalidomide in myelodysplastic syndromes.
The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians. In this paper the current classification and the recent advances in the understanding the disease mechanisms are reviewed. The recent therapeutic advances are also indicated, such as intensive and low-dose chemotherapy, new drugs, erythropoietin and colony-stimulating factors. However, the work has been focused on thalidomide, its therapeutic potential, its modes of actions, side effects, indications and future applications.
Zorat
F
F
Università degli Studi di Trieste, Dipartimento di Medicina Clinica & Neurologia, Ospedale di Cattinara, Italy.
Pozzato
G
G
D000753:Anemia, Refractory / Q000188:drug therapy; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002869:Chromosome Aberrations; D003248:Constipation / Q000139:chemically induced; D016207:Cytokines / Q000037:antagonists & inhibitors; D004417:Dyspnea / Q000139:chemically induced; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D013792:Thalidomide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D016207:Cytokines; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide